SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-20-118192
Filing Date
2020-04-24
Accepted
2020-04-24 08:00:36
Documents
8
Period of Report
2020-06-05
Effectiveness Date
2020-04-24

Document Format Files

Seq Description Document Type Size
1 DEF 14A d850972ddef14a.htm DEF 14A 373412
2 GRAPHIC g850972g06m20.jpg GRAPHIC 22716
3 GRAPHIC g850972g11y77.jpg GRAPHIC 26592
4 GRAPHIC g850972g21j11.jpg GRAPHIC 24658
5 GRAPHIC g850972g25y45.jpg GRAPHIC 37689
6 GRAPHIC g850972g48b93.jpg GRAPHIC 34934
7 GRAPHIC g850972g56z83.jpg GRAPHIC 16586
8 GRAPHIC g850972g57f70.jpg GRAPHIC 22487
  Complete submission text file 0001193125-20-118192.txt   630728
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38541 | Film No.: 20812508
SIC: 2834 Pharmaceutical Preparations